Compositions et procédés de traitement de troubles associés à la rétention de sel ou de fluide

Compositions and methods for treating disorders associated with salt or fluid retention

Abstract

La présente invention concerne des procédés de réduction de risque ou de traitement d'un trouble associé à la rétention de sel ou de fluide chez un patient. Les procédés comprennent l'administration à un patient d'un agent choisi parmi : a) un agent qui réduit l'absorption de sodium dans l'intestin; b) un agent qui accroît la sécrétion d'anions dans l'intestin; ou c) un agent qui à la fois réduit l'absorption de sodium dans l'intestin et accroît la sécrétion d'anions dans l'intestin.
Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    CA-2522895-A1November 11, 2004Waratah Pharmaceuticals, Inc., Stephen J. Brand, Antonio CruzUtilisation combinee d'agonistes de facteur de croissance de keratinocytes et de composes de gastrine
    JP-H11240841-ASeptember 07, 1999Nissin Food Prod Co Ltd, Univ Kyoto, 京都大学長, 日清食品株式会社Inhibitor of hypertension

NO-Patent Citations (6)

    Title
    FORDTRAN J.S. ET AL.: 'The mechanisms of sodium absorption in the human small intestine' J. CLIN. INVEST. vol. 47, no. 4, April 1968, pages 884 - 900, XP008124250
    HYPERTENSION vol. 37, no. 2, PART 2, February 2001, pages 467 - 471, XP008124233
    SAHAY M. ET AL.: 'Sodium transporters in kidney role in health and disease' J. ASSOC. PHYSICIANS INDIA vol. 55, February 2007, pages 135 - 139, XP008124279
    See also references of EP 2152266A1
    SICA D.A.: 'Sodium and water retention in heart failure and diuretic therapy: basic mechanisms' CLEVE CLIN. J. MED. vol. 73, no. SUPPL. 2, June 2006, pages S2 - S7, XP008124251
    VALLON V. ET AL.: 'The salt paradox and its possible implications in managing hypertensive diabetic patients' CURR. HYPERTENS. REP. vol. 7, no. 2, April 2005, pages 141 - 147, XP008124280

Cited By (38)

    Publication numberPublication dateAssigneeTitle
    CN-102858361-AJanuary 02, 2013药物协和股份有限公司Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
    CN-105037177-ANovember 11, 2015青岛科技大学Method for preparing S-metoprolol by supercritical crystallization process
    JP-2012510527-AMay 10, 2012シナジー ファーマシューティカルズ インコーポレイテッドグアニル酸シクラーゼcアゴニストの製剤およびその使用方法
    JP-2015038070-AFebruary 26, 2015シナジー ファーマシューティカルズ インコーポレイテッド, Synergy Pharmaceuticals Inc, シナジー ファーマシューティカルズ インコーポレイテッドグアニル酸シクラーゼcアゴニストの製剤およびその使用方法
    JP-2017048245-AMarch 09, 2017シナジー ファーマシューティカルズ インコーポレイテッド, Synergy Pharmaceuticals Inc, シナジー ファーマシューティカルズ インコーポレイテッドPharmaceutical preparation of guanylate cyclase c agonist, and method for using the same
    US-7879802-B2February 01, 2011Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8034782-B2October 11, 2011Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8114831-B2February 14, 2012Synergy Pharmaceuticals Inc.Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
    US-8207295-B2June 26, 2012Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8222201-B2July 17, 2012Ritesh Sanghvi, Andreas Grill, Rahul Surana, Haijian ZhuCrystalline form of linaclotide
    US-8293704-B2October 23, 2012Ritesh Sanghvi, Andreas Grill, Rahul Surana, Zhu Hiajian JimCrystalline form of linaclotide
    US-8357775-B2January 22, 2013Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8367800-B2February 05, 2013Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8497348-B2July 30, 2013Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8541448-B2September 24, 2013Ardelyx, Inc.Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
    US-8569246-B2October 29, 2013Synergy Pharamaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8637451-B2January 28, 2014Synergy Pharmaceuticals Inc.Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
    US-8664354-B2March 04, 2014Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8716224-B2May 06, 2014Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8901075-B2December 02, 2014Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-8969377-B2March 03, 2015Ardelyx, Inc.Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
    US-8969514-B2March 03, 2015Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
    US-9006281-B2April 14, 2015Ardelyx, Inc.Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
    US-9089612-B2July 28, 2015Synergy Pharmaceuticals, Inc.Method of inhibiting bile acid absorption by administering an agonist of a guanylate cyclase receptor
    US-9238677-B2January 19, 2016Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-9266926-B2February 23, 2016Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-9408840-B2August 09, 2016Ardelyx, Inc.Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
    US-9505805-B2November 29, 2016Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-9580471-B2February 28, 2017Synergy Pharmaceuticals, Inc.Process of preparing guanylate cyclase C agonists
    US-9610321-B2April 04, 2017Synergy Pharmaceuticals, Inc.Formulations of guanylate cyclase C agonists and methods of use
    US-9616097-B2April 11, 2017Synergy Pharmaceuticals, Inc.Formulations of guanylate cyclase C agonists and methods of use
    US-9708367-B2July 18, 2017Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase and their uses
    US-9814752-B2November 14, 2017Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
    WO-2009149278-A1December 10, 2009Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    WO-2010065751-A3September 15, 2011Synergy Pharmaceuticals, Inc.Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
    WO-2011020054-A1February 17, 2011Ironwood Pharmaceuticals Inc.Procédé de modulation de l'effet pharmacodynamique d'agonistes des récepteurs de guanylate cyclase administrés par voie orale
    WO-2011069038-A3March 01, 2012Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
    WO-2012118972-A3December 27, 2012Synergy Pharmaceuticals Inc.Procédé de préparation d'agonistes du guanylate cyclase c